Evidence map›Paper›PMID 15726334›Full record

ArticlePsychopharmacology2005

Examining SLV-323, a novel NK1 receptor antagonist, in a chronic psychosocial stress model for depression.

Boldizsár Czéh, Olga Pudovkina, Marieke G C van der Hart, Mária Simon, Urs Heilbronner, Thomas Michaelis, Takashi Watanabe, Jens Frahm, Eberhard Fuchs

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Innovative drugs to treat depression: did animal models fail to be predictive or did clinical trials fail to detect effects?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Boldizsár CzéhClinical Neurobiology Laboratory, German Primate Center, Kellnerweg 4, 37077 Göttingen, Germany. bczeh@dpz.gwdg.de
Olga Pudovkina
Marieke G C van der Hart
Mária Simon
Urs Heilbronner
Thomas Michaelis
Takashi Watanabe
Jens Frahm
Eberhard Fuchs
German Primate Center · DEMax Planck Institute for Biophysical Chemistry · DESolvay (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleSubstance P antagonists have been proposed as candidates for a new class of antidepressant compounds.

objectivesWe examined the effects of SLV-323, a novel neurokinin 1 receptor (NK1R) antagonist, in the chronic psychosocial stress paradigm of adult male tree shrews.

methodsAnimals were subjected to a 7 day period of psychosocial stress before being treated daily with SLV-323 (20 mg kg(-1) day(-1)). The psychosocial stress continued throughout the treatment period of 28 days. Brain metabolite concentrations were determined in vivo by proton magnetic resonance spectroscopy. Norepinephrine excretion was monitored from daily urine samples, and serum testosterone concentrations were measured at the end of the experiment. All animals were videotaped daily to analyze scent-marking behavior and locomotor activity. Cell proliferation in the dentate gyrus and hippocampal volume were measured postmortem.

resultsStress significantly decreased cerebral concentrations of N-acetyl-aspartate, total creatine, and choline-containing compounds in vivo and resulted in an increase of urinary norepinephrine and decrease of serum testosterone concentrations. Moreover, stressed animals displayed decreased scent-marking behavior and locomotor activity. The proliferation rate of the granule precursor cells in the dentate gyrus was reduced, and hippocampal volume was mildly decreased. The stress-induced alterations in the central nervous system were partially prevented by concomitant administration of SLV-323, while drug treatment had only a minor effect on the stress-induced behavioral changes.

conclusionsThe novel NK1R antagonist SLV-323 has certain antidepressant-like effects in a valid animal model of depression.

Indexed as

Neurokinin-1 Receptor AntagonistsAnimalsBehavior, AnimalCell ProliferationDentate GyrusDepressionHippocampusMagnetic Resonance SpectroscopyMaleModels, AnimalMotor ActivityNorepinephrineReceptors, Neurokinin-1Stress, PsychologicalTestosteroneTime FactorsNeurokinin-1 Receptor AntagonistsNorepinephrineReceptors, Neurokinin-1Testosterone

Identifiers

PMID15726334
OpenAlexW2121198748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.